Regulation of the human polymorphonuclear leukocyte inflammatory response by inhibitors of arachidonic acid metabolism.
Perturbation of the neutrophil membrane by opsonized zymosan particles activates the cell's "respiratory burst." Associated with this activation process is the generation of highly reactive oxygen products, including superoxide, and the release of lysosomal enzymes. Membrane activation also stimulates arachidonic acid metabolism and the generation of a wide variety of products through both the lipoxygenase and cyclooxygenase pathways. In isolated human neutrophils, we have evaluated the effects inhibitors of cyclooxygenase and lipoxygenase upon opsonized zymosan stimulated chemiluminescence, superoxide generation, oxygen consumption, and beta-glucuronidase release. Nordihydroguaiaretic acid (NDGA), an inhibitor of the lipoxygenase enzyme, suppressed chemiluminescence, superoxide generation, oxygen consumption, and beta-glucuronidase release. Both indomethacin, a cyclooxygenase inhibitor, and 5,8,11,14 - eicosatetraynoic acid (ETYA) an inhibitor of both cyclooxygenase and lipoxygenase, inhibited all tested neutrophil functions. However, when compared to NDGA, indomethacin and ETYA were considerably less potent. Our observations suggest that the lipooxygenase derived metabolites play a predominant regulatory role in these neutrophil inflammatory functions.
D000925:Anticoagulants / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002396:Catechols / Q000494:pharmacology; D003574:Cytochrome c Group / Q000378:metabolism; D015118:Eicosapentaenoic Acid; D005231:Fatty Acids, Unsaturated / Q000494:pharmacology; D005966:Glucuronidase / Q000378:metabolism; D006801:Humans; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007249:Inflammation / Q000503:physiopathology*; D008163:Luminescent Measurements; D008247:Lysosomes / Q000201:enzymology; D009637:Masoprocol; D009504:Neutrophils / Q000187:drug effects*; D010084:Oxidation-Reduction; D010101:Oxygen Consumption / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism; D014969:Xanthine Oxidase / Q000378:metabolism; D015054:Zymosan / Q000494:pharmacology
D000925:Anticoagulants; D000975:Antioxidants; D001095:Arachidonic Acids; D002396:Catechols; D003574:Cytochrome c Group; D005231:Fatty Acids, Unsaturated; D013481:Superoxides; D016718:Arachidonic Acid; D009637:Masoprocol; D015054:Zymosan; D015118:Eicosapentaenoic Acid; D014969:Xanthine Oxidase; D005966:Glucuronidase; D007213:Indomethacin